Dear all,

To answer directly to the question of capripoxvirus recombinant vaccine approach developed by CIRAD, we have generated H-PPR and F-PPR recombinant capripoxviruses that protect against both diseases. We also generated recombinant Rift Valley fever-capripoxvirus that is imunologically active (no challenge studies so far). We are thinking about a trivalent vaccine, for instance PPR-Rift-capripoxvirus.

The advantages of the capripoxvirus in our hands are:

- easy platform to insert and express in target animals several different transgenes (e.g.:  a perfectly characterized immunogen of Brucella could be inserted and tested)
- long lasting immunity after one shoot (at least one year of protection)
- DIVA property for the diseases targeted by the inserts (in the case of PPR, we induce anti-H or anti-F immune responses and we test the serum anti-N antibodies by a commercial ELISA)
- thermal stability (2 weeks in liquid form at +36°C)

However, the current drawbacks are:

- validations are still required before use in the field: purity check (possibly by deep sequencing without a priori), upscaling of the production, etc... (according to the requirements of the private industry and international regulations)
- pre-immunity interference with the vaccine: first vaccination with this type of vaccine in a ruminant population infected by wild-type capripoxvirus may not protect more than 50% of the animals against pox AND PPR. This means that the first year, a combination of recombinant capripox and Nigeria75/1 vaccine [a paper in Vaccine (Chaudary et al, 2009) showed that both vaccines could be combined in a single injection] should be applied to reduce the prevalence of capripoxvirus and then the next year, only the recombinant capripoxvirus could be used
- Lack of funds to speed up finalization of laboratory work before transfer of the vaccine to the private sector

Regards

For CIRAD, Emmanuel Albina


Le 25/02/2014 12:19, Paul Rossiter a écrit :
[log in to unmask]" type="cite">
Dear moderator and dear all,
 
I agree with that we should include other diseases  such as sheep and goats pox in the progressive control of PPR in small ruminants. If I well remember Cirad had in collaboration with LANAVET (Cameroon) developped recombinant vaccine against PPR using Capripox as support. I don't know if this vaccine is still available ; if yes so we can easily go for progressive control of PPR and SGP. I think Dr Adama or Ngagnou could answer to this.
 
Kind regards!
Bidjeh Kebkiba,
Head of virology Unit, IRED (Chad),
Route de farcha,
PO box 433, Ndjamena- Chad. 


To unsubscribe from the FAO-AnimalHealth-L list, click the following link:
https://listserv.fao.org/cgi-bin/wa?SUBED1=FAO-AnimalHealth-L&A=1


--
Signature electronique


To unsubscribe from the FAO-AnimalHealth-L list, click the following link:
https://listserv.fao.org/cgi-bin/wa?SUBED1=FAO-AnimalHealth-L&A=1